Research programme: neuronal nitric oxide synthase inhibitors - AstraZenecaAlternative Names: Neuronal nitric oxide synthase inhibitors research programme - AstraZeneca
Latest Information Update: 24 Aug 2006
At a glance
- Originator AstraZeneca
- Mechanism of Action Nitric oxide synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 24 Aug 2006 Discontinued - Preclinical for Parkinson's disease in Sweden (unspecified route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 11 Feb 1998 New profile